FirstWord Pharma’s Post

Antibody-drug conjugates (ADCs) offer an exciting look into the future of cancer therapy. This article showcases the role of LC-MS/MS in enhancing the development and analysis of these potent cancer-fighting drugs. Understand why LC-MS/MS is the go-to technique for accurate, efficient, and cost-effective drug analysis. #ADCDrugs #LCMS #BioassayOptimization #DrugDevelopment #CancerResearch https://hubs.li/Q02JG6dy0

Traditional chemotherapy has long been a cornerstone of cancer treatment, but it often comes with significant side effects. Enter Antibody-Drug Conjugates (ADCs), which offer a more targeted approach by harnessing the power of monoclonal antibodies and cytotoxic drugs. Our latest blog discusses the composition, mechanism of action, and bioanalytical strategies essential for developing these promising therapies. Discover how ADCs are setting a new standard in oncology. #CancerTreatment #Oncology #AntibodyDrugConjugates #Pharma #ClinicalBioanalysis #InnovationInHealthcare Read more: https://hubs.li/Q02MCyL00

Antibody-drug conjugates (ADCs) offer an exciting look into the future of cancer therapy. This article showcases the role of LC-MS/MS in enhancing the development and analysis of these potent cancer-fighting drugs. Understand why LC-MS/MS is the go-to technique for accurate, efficient, and cost-effective drug analysis. #ADCDrugs #LCMS #BioassayOptimization #DrugDevelopment #CancerResearch https://hubs.li/Q02JGhRr0

Traditional chemotherapy has long been a cornerstone of cancer treatment, but it often comes with significant side effects. Enter Antibody-Drug Conjugates (ADCs), which offer a more targeted approach by harnessing the power of monoclonal antibodies and cytotoxic drugs. Our latest blog discusses the composition, mechanism of action, and bioanalytical strategies essential for developing these promising therapies. Discover how ADCs are setting a new standard in oncology. #CancerTreatment #Oncology #AntibodyDrugConjugates #Pharma #ClinicalBioanalysis #InnovationInHealthcare Read more: https://hubs.li/Q02MCwXl0

Discover what HCPs are saying about the future of #Oncology treatments. Our research highlights six emerging #cancer drugs that #HCPs have shared their opinions about online: - Immunotherapies - Targeted therapies - CAR-T cell therapies - Antibody-drug conjugates - Vaccines for cancer - Radiopharmaceutical therapies Download our whitepaper for in-depth insights into HCP perspectives on the future of Oncology. #ASCO24 https://lnkd.in/et3Fcsmh

Get ready to dive deep into the preliminary data of Decoy20's Phase 1 study with Roger Waltzman, MD, Chief Medical Officer at Indaptus Therapeutics, Inc. Join us as we explore the implications of this novel therapy for patients with advanced solid tumours and the future of immuno-oncology. To learn more about the event, click here: https://lnkd.in/gnvAu9yS #oncology #oncologyresearch #cancer #medicine #oncologia #ngioboston2024 #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets #bostonconference2024

🚀 Exciting News in the World of Antibody Drug Conjugates!🔬 🌟 Dive into the latest edition of ADC Digest for the first week of May 2024, where groundbreaking advancements are illuminating the field of Antibody Drug Conjugates! 💊 Pfizer and Genmab’s ADC Tivdak receive full FDA approval for recurrent or metastatic cervical cancer 💊 AstraZeneca, Daiichi tout Enhertu trial win in earlier, broader HER2-low breast cancer Stay tuned for more updates and breakthroughs in the realm of Antibody-Drug Conjugates! #ADC #MedicalInnovations #CancerResearch #approval #Innovation #ADCnews #CIScientists #Antibodydrugconjugate

Delighted to announce the publication of our article 'Prognostic Biomarkers for Triple-Negative Breast Cancer: A Narrative Review' in the International Journal of Pharmaceutical Sciences. This work sheds light on the critical markers that could revolutionize the prognosis and treatment of triple-negative breast cancer. #BreastCancerAwareness #MedicalResearch #InnovationInHealthcare"

Mark your calendars for the 8th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference in London, endorsed by Medicon Valley Alliance as Our Supporting Association Partners. Join us on 07th-8th March 2024 at Park Plaza Victoria to explore the forefront of cancer immunotherapy To explore more, click here: https://lnkd.in/dvuWh2a6 #oncology #oncologyresearch #cancer #medicine #oncologia #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets  

How can we inspire adoption of innovative cancer diagnostics? Communication between industry, pharmaceutical companies, oncologists, and pathologists is key to ensuring rapid tumour diagnosis in breast cancer. And use of MammaTyper® is a way to enable innovation. As Dr Dario DeBiase says, MammaTyper® means you can continue to work well, whilst adding in “another tool to help you provide more reliable results.”  #BreastCancerDiagnosis #CancerInnovation